ReNeuron Group plc - Share Purchase by Executive Chairman
ReNeuron Group plc
("ReNeuron" or the "Company")
Share Purchase by Executive Chairman
ReNeuron Group plc (AIM: RENE), a
|
Name |
Title |
Number of Ordinary Shares purchased |
Resulting beneficial interest in the Company's Ordinary Shares |
Percentage of Company's Total Voting Rights |
|
|
Executive Chairman |
150,000 |
550,000 |
0.96% |
ENDS
Enquiries:
|
ReNeuron |
||
|
Iain Ross, Executive Chairman |
Via Walbrook PR |
|
|
John Hawkins, Chief Financial Officer |
|
|
|
|
|
|
|
Allenby Capital Limited (Nominated Adviser and Broker) |
+44 (0)20 3328 5656 |
|
|
James Reeve/George Payne/Dan Dearden-Williams (Corporate Finance) |
|
|
|
Stefano Aquilino (Sales & Corporate Broking) |
|
|
|
|
|
|
|
Walbrook PR (Media & Investor Relations) |
+44 (0)20 7933 8780 or reneuron@walbrookpr.com |
|
|
Paul McManus / Alice Woodings |
+44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.
Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
(Disclosure in relation to ordinary shares purchased by Directors and PDMRs)
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||||||||
|
a) |
Name |
Iain Ross |
||||||||||||
|
2 |
Reason for the notification |
|||||||||||||
|
a) |
Position/status |
Executive Chairman and Director |
||||||||||||
|
b) |
Initial notification /Amendment |
Initial notification |
||||||||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||
|
a) |
Name |
ReNeuron Group plc |
||||||||||||
|
b) |
LEI |
2138003TU12CQ5TZO137 |
||||||||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||||||||
|
a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares RENE - GB00BF5G6K95 |
||||||||||||
|
b) |
Nature of the transaction |
Acquisition of ordinary shares |
||||||||||||
|
c) |
Price(s) and volume(s)
|
|
||||||||||||
|
d)
|
Aggregated information |
150,000 ordinary shares at an average price of |
||||||||||||
|
e) |
Date of the transaction |
|
||||||||||||
|
f) |
Place of the transaction |
London Stock Exchange AIM Market |
||||||||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE